White Shield

Interest-Based Ads

Advertising Cookies: We would like to set third-party advertising cookies on your browser for this health-related website to help us serve relevant health-related advertisements to you about our products or services when you visit other websites. For more information, visit our Privacy Policy. Do you want to set these advertising cookies on this browser?

Patients HCP
This site is for US residents only.
Treatment milestones. Al, real SCEMBLIX patient. Al was compensated for his time.

Treatment goals track how well your medication is working

When setting treatment goals, you and your doctor should consider how well the medication is working and its possible side effects.

Monitor icon
Tracking results
 

Your doctor will monitor your blood regularly to see how your treatment is working. A key measure is BCR::ABL1 levels in your blood: the lower, the better.

Milestone icon
Measuring response
 

Reaching major molecular response (MMR) in the first year on treatment is an important milestone. MMR is achieved when the level of abnormal BCR::ABL1 gene in the blood has gone down to 0.1% or less compared to when you were first diagnosed. This means only 1 in 1,000 cells or less have the BCR::ABL1 gene. 

Hand raise icon
Staying involved
 

Stay actively involved in your treatment and keep your doctor in the loop about all your symptoms and side effects.

Doctor Discussion Guide icon
Start on a Ph+ CML in chronic phase treatment that may help you achieve your treatment goals
 

Talk to your doctor about your treatment goals and how SCEMBLIX may help.

Download Doctor Discussion Guide

Ph+ CML-CP, Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase; TKIs, tyrosine kinase inhibitors.

*SCEMBLIX was studied vs GLEEVEC® (imatinib), TASIGNA® (nilotinib), Sprycel ® (dasatinib), and Bosulif ® (bosutinib). Sprycel is a registered trademark of Bristol-Myers Squibb Company. Bosulif is a registered trademark of Pfizer Inc.